COMMUNIQUÉS West-GlobeNewswire

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
02/06/2026
Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to [...]
CorVel Marks 35 Years on Nasdaq, Signals Next Phase of Long-Term Innovation and Growth
02/06/2026
FORT WORTH, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced that it will mark its 35th anniversary as a publicly traded company listed on the Nasdaq Stock Market. Members of [...]
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
02/06/2026
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 ( [...]
Ocugen to Participate in Upcoming June Investor and Industry Conferences
02/06/2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will [...]
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
02/06/2026
Orphan Drug Designation is intended to support the development of therapies for rare diseases affecting fewer than 200,000 people in the United States MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp [...]
Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
02/06/2026
— Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures — — Advancing second-generation Emperor TAH development toward a fully implantable system — TUCSON, [...]
Augustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific Sessions
02/06/2026
Poster will feature in vivo efficacy profile of one of Augustine’s HDAC6 inhibitor development candidates LEUVEN, Belgium – 2 June 2026 – Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company [...]
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
02/06/2026
RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
02/06/2026
FDA considered the planned HER-096 Phase 2a study design appropriate Study design finalized; approximately 100 patients to be enrolled More than 50% of Phase 2 funding secured or identified Espoo, Finland, 2 June 2026: [...]
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
02/06/2026
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- [...]
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
02/06/2026
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial [...]
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
02/06/2026
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival benefit: 12-month [...]
SEED Therapeutics Highlights Clinical Advancement and Broad Oncology Potential of ST-01156, an RBM39 Molecular Glue Degrader in First-in-Human in Phase 1 Studies, at ASCO 2026
02/06/2026
Oral, Selective RBM39 Degrader Under Evaluation in Phase 1 Trial; Preclinical Data Support Expansion Potential Across Ewing Sarcoma, Hepatocellular Carcinoma, KRAS-Mutant Cancers, Neuroblastoma, and Other RBM39- [...]
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
02/06/2026
Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN) Revised ORIGIN 3 eGFR analysis now [...]
Telix and United Imaging Announce Strategic Theranostics Collaboration
02/06/2026
Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms. Initial focus on TLX101-Px (Pixclara® 1 , Floretyrosine F 18) in the [...]
Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York
02/06/2026
This collaboration marks Lumexa Imaging’s ninth joint venture and advances the company’s health system growth strategy RALEIGH, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation’s [...]
Soleo Health Acquires Realo Specialty Care Pharmacy and BluHaven Management, Expanding Footprint in Mid-Atlantic Region
02/06/2026
FRISCO, Texas and MORRISVILLE, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an independent specialty pharmacy and infusion therapy provider, announced today the Company acquired Realo Specialty Care Pharmacy (“ [...]
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
02/06/2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD Company to highlight AXPAXLI™ wet [...]
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
02/06/2026
Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study’s primary endpoint Topline results for the fully enrolled open-label study are expected in the second half of 2026 [...]

Pages